JP2011083291A5 - - Google Patents

Download PDF

Info

Publication number
JP2011083291A5
JP2011083291A5 JP2011010778A JP2011010778A JP2011083291A5 JP 2011083291 A5 JP2011083291 A5 JP 2011083291A5 JP 2011010778 A JP2011010778 A JP 2011010778A JP 2011010778 A JP2011010778 A JP 2011010778A JP 2011083291 A5 JP2011083291 A5 JP 2011083291A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
antigen
monoclonal antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011010778A
Other languages
English (en)
Other versions
JP2011083291A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011083291A publication Critical patent/JP2011083291A/ja
Publication of JP2011083291A5 publication Critical patent/JP2011083291A5/ja
Pending legal-status Critical Current

Links

Claims (33)

  1. M-CSFに特異的に結合するモノクローナル抗体またはの抗原結合断片であって、該抗体が、
    SEQ ID NO:30およびSEQ ID NO:32のそれぞれ重鎖可変ドメインおよび軽鎖可変ドメインの;または
    SEQ ID NO:26およびSEQ ID NO:28のそれぞれ重鎖可変ドメインおよび軽鎖可変ドメインの、
    CDR1、CDR2およびCDR3のアミノ酸配列を含む、モノクローナル抗体またはその抗原結合断片
  2. 抗体が、CDRと同じ可変ドメインから選択されるFR1、FR2、FR3、およびFR4のアミノ酸配列の1つもしくは複数を含む、請求項1記載のモノクローナル抗体または抗原結合断片。
  3. M-CSFに特異的に結合するモノクローナル抗体またはその抗原結合断片であって、該抗体が、抗体8.10.3F、および抗体9.14.4Iからなる群より選択される抗体のCDR1、CDR2、およびCDR3のアミノ酸配列を含む、モノクローナル抗体またはその抗原結合断片。
  4. 抗体が、
    SEQ ID NO:30およびSEQ ID NO:32のそれぞれ重鎖可変ドメインおよび軽鎖可変ドメインの;または
    SEQ ID NO:26およびSEQ ID NO:28のそれぞれ重鎖可変ドメインおよび軽鎖可変ドメインの、
    CDR1の開始部位からCDR3の末端のアミノ酸配列を含む、請求項1記載のモノクローナル抗体または抗原結合断片。
  5. 抗体が、
    SEQ ID NO:30およびSEQ ID NO:32のそれぞれ重鎖可変ドメイン(V H )および軽鎖可変ドメイン(V L )のアミノ酸配列を含む;または
    SEQ ID NO:26およびSEQ ID NO:28のそれぞれ重鎖可変ドメイン(V H )および軽鎖可変ドメイン(V L )のアミノ酸配列を含む、
    請求項4記載のモノクローナル抗体または抗原結合断片。
  6. 抗体が、抗体8.10.3F、および抗体9.14.4Iからなる群より選択される抗体のV H 、およびV L のアミノ酸配列を含む、請求項3記載のモノクローナル抗体または抗原結合断片。
  7. M-CSFに特異的に結合するモノクローナル抗体であって、該抗体の重鎖のアミノ酸配列がシグナル配列を含まないSEQ ID NO:30であり、かつ該抗体の軽鎖のアミノ酸配列がシグナル配列を含まないSEQ ID NO:32である、モノクローナル抗体。
  8. M-CSFに特異的に結合するモノクローナル抗体であって、該抗体の重鎖のアミノ酸配列がシグナル配列を含まないSEQ ID NO:26であり、かつ抗体の軽鎖のアミノ酸配列がシグナル配列を含まないSEQ ID NO:28である、モノクローナル抗体。
  9. 抗体または抗原結合断片の重鎖のC末端のリシンが存在しない、請求項1〜8のいずれか一項記載のモノクローナル抗体または抗原結合断片。
  10. 請求項1〜9のいずれか一項記載の抗体または抗原結合断片および薬学的に許容される担体を含む、薬学的組成物。
  11. 抗体が、モノクローナルの抗M-CSF抗体8.10.3Fまたは9.14.4Iである、請求項10記載の薬学的組成物。
  12. 請求項1〜9のいずれか一項記載の抗体または抗原結合断片、および薬学的に許容される担体を含む、以下からなる群から選択される状態を有する患者の治療に用いられる薬学的組成物:
    関節炎、乾癬性関節炎、強直性脊椎炎、ライター症候群、慢性関節リウマチ、痛風、外傷性関節炎、風疹性関節炎、および急性滑膜炎、ならびに他の関節炎条件、敗血症、敗血症性ショック、内毒素ショック、グラム陰性菌性敗血症、毒素ショック症候群、アルツハイマー病、卒中、神経外傷、喘息、成人呼吸窮迫症候群、脳性マラリア、慢性肺炎、珪肺症、肺サルコイドーシス、骨吸収疾患、骨粗鬆症、再狭窄、心臓および腎臓の再灌流傷害、血栓症、糸球体腎炎、糖尿病、移植片対宿主反応、同種移植拒絶反応、炎症性腸疾患、クローン病、潰瘍性大腸炎、多発性硬化症、筋肉変性、湿疹、接触皮膚炎、乾癬、日焼け、ならびに結膜炎ショック。
  13. 状態が慢性関節リウマチである、請求項12記載の薬学的組成物。
  14. 請求項1〜9のいずれか一項記載の抗体または抗原結合断片、および薬学的に許容される担体を含む、固形腫瘍、癌、または非固形腫瘍を有する患者の治療に用いられる薬学的組成物。
  15. 肉腫の治療に用いられる、請求項14記載の薬学的組成物。
  16. リンパ腫の治療に用いられる、請求項14記載の薬学的組成物。
  17. 請求項1〜9のいずれか一項記載の抗体または抗原結合断片、および薬学的に許容される担体を含む、以下からなる群から選択される状態を有する患者の治療に用いられる薬学的組成物:
    脳腫瘍、扁平細胞癌、膀胱癌、胃の癌、膵臓癌、乳癌、頭部癌、頸部癌、肝臓癌、食道癌、前立腺癌、結腸直腸癌、肺癌、腎癌、腎臓癌、卵巣癌、子宮癌、婦人科癌、上咽頭癌、甲状腺癌、副甲状腺癌、副腎腺癌、小腸癌、結腸癌、胃癌、直腸癌、肛門癌、皮膚癌、頭頸部の癌、陰門の癌、陰茎癌、黒色腫、血液の癌、骨髄の癌、およびリンパ系の癌。
  18. 抗体がモノクローナルの抗M-CSF抗体8.10.3Fまたは9.14.4Iである、請求項12〜17のいずれか一項記載の薬学的組成物。
  19. 請求項1〜9のいずれか一項記載のモノクローナル抗体もしくは抗原結合断片を産生する、単離された細胞系列。
  20. 抗体8.10.3F、抗体9.14.4I、および前記の抗体の一つと同じアミノ酸配列を有する抗体からなる群より選択されるモノクローナル抗体を産生する、請求項19記載の単離された細胞系列。
  21. 請求項1〜9のいずれか一項記載のモノクローナル抗体の、重鎖もしくはその抗原結合断片、軽鎖もしくはその抗原結合断片、または重鎖および軽鎖の両方もしくはその抗原結合断片をコードするヌクレオチド配列を含む、単離された核酸分子。
  22. 請求項21記載の核酸分子を含むベクター。
  23. 核酸分子が機能的に連結された発現制御配列を含む、請求項22記載のベクター。
  24. 請求項22または23記載のベクターまたは請求項21記載の核酸分子を含む、単離された宿主細胞。
  25. 請求項1〜9のいずれか一項記載の抗体または抗原結合断片の、重鎖をコードする核酸分子および軽鎖をコードする核酸分子を含む、請求項24記載の単離された宿主細胞。
  26. 抗M-CSF抗体またはその抗原結合断片を作製する方法であって、請求項24記載の宿主細胞、または請求項19記載の細胞系列を適切な条件で培養する段階、ならびに抗体または抗原結合断片を回収する段階を含む、方法。
  27. 非ヒトトランスジェニック動物、または植物であって、
    シグナル配列を含むもしくは含まないSEQ ID NO:30およびSEQ ID NO:32のアミノ酸配列をそれぞれ有する重鎖をコードする単離された核酸分子および軽鎖をコードする単離された核酸分子;または
    シグナル配列を含むもしくは含まないSEQ ID NO:26およびSEQ ID NO:28のアミノ酸配列をそれぞれ有する重鎖をコードする単離された核酸分子および軽鎖をコードする単離された核酸分子
    を含み、該核酸分子を発現する、非ヒトトランスジェニック動物、または植物。
  28. M-CSFに特異的に結合するモノクローナル抗体またはその抗原結合部分であって、該抗体が、モノクローナル抗体8.10.3Fの重鎖アミノ酸配列(シグナル配列を含まないSEQ ID NO:30)と少なくとも90%同一である重鎖アミノ酸配列を含む、モノクローナル抗体またはその抗原結合部分。
  29. 請求項28記載のモノクローナル抗体またはその抗原結合部分であって、重鎖がモノクローナル抗体8.10.3Fの重鎖アミノ酸配列(シグナル配列を含まないSEQ ID NO:30)と少なくとも95%同一である重鎖アミノ酸配列を含む、モノクローナル抗体またはその抗原結合部分。
  30. 請求項29記載のモノクローナル抗体またはその抗原結合部分であって、重鎖がモノクローナル抗体8.10.3Fの重鎖アミノ酸配列(シグナル配列を含まないSEQ ID NO:30)と少なくとも99%同一である重鎖アミノ酸配列を含む、モノクローナル抗体またはその抗原結合部分。
  31. M-CSFに特異的に結合するモノクローナル抗体またはその抗原結合部分であって、該抗体が、モノクローナル抗体8.10.3Fの軽鎖アミノ酸配列(シグナル配列を含まないSEQ ID NO:32)と少なくとも90%同一である軽鎖アミノ酸配列を含む、モノクローナル抗体またはその抗原結合部分。
  32. 請求項31記載のモノクローナル抗体またはその抗原結合部分であって、軽鎖がモノクローナル抗体8.10.3Fの軽鎖アミノ酸配列(シグナル配列を含まないSEQ ID NO:32)と少なくとも95%同一である軽鎖アミノ酸配列を含む、モノクローナル抗体またはその抗原結合部分。
  33. 請求項32記載のモノクローナル抗体またはその抗原結合部分であって、軽鎖がモノクローナル抗体8.10.3Fの軽鎖アミノ酸配列(シグナル配列を含まないSEQ ID NO:32)と少なくとも99%同一である軽鎖アミノ酸配列を含む、モノクローナル抗体またはその抗原結合部分。
JP2011010778A 2003-09-10 2011-01-21 M−csfに対する抗体 Pending JP2011083291A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50216303P 2003-09-10 2003-09-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007263538A Division JP2008067710A (ja) 2003-09-10 2007-10-09 M−csfに対する抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013147604A Division JP5829653B2 (ja) 2003-09-10 2013-07-16 M−csfに対する抗体

Publications (2)

Publication Number Publication Date
JP2011083291A JP2011083291A (ja) 2011-04-28
JP2011083291A5 true JP2011083291A5 (ja) 2012-04-12

Family

ID=33300142

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2006526276A Withdrawn JP2007528724A (ja) 2003-09-10 2004-09-09 M−csfに対する抗体
JP2007263538A Pending JP2008067710A (ja) 2003-09-10 2007-10-09 M−csfに対する抗体
JP2011010778A Pending JP2011083291A (ja) 2003-09-10 2011-01-21 M−csfに対する抗体
JP2013147604A Expired - Fee Related JP5829653B2 (ja) 2003-09-10 2013-07-16 M−csfに対する抗体
JP2015097050A Expired - Fee Related JP6106711B2 (ja) 2003-09-10 2015-05-12 M−csfに対する抗体
JP2016204288A Expired - Fee Related JP6412903B2 (ja) 2003-09-10 2016-10-18 M−csfに対する抗体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006526276A Withdrawn JP2007528724A (ja) 2003-09-10 2004-09-09 M−csfに対する抗体
JP2007263538A Pending JP2008067710A (ja) 2003-09-10 2007-10-09 M−csfに対する抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013147604A Expired - Fee Related JP5829653B2 (ja) 2003-09-10 2013-07-16 M−csfに対する抗体
JP2015097050A Expired - Fee Related JP6106711B2 (ja) 2003-09-10 2015-05-12 M−csfに対する抗体
JP2016204288A Expired - Fee Related JP6412903B2 (ja) 2003-09-10 2016-10-18 M−csfに対する抗体

Country Status (42)

Country Link
US (8) US7592430B2 (ja)
EP (2) EP3170840B1 (ja)
JP (6) JP2007528724A (ja)
KR (2) KR100938452B1 (ja)
CN (2) CN102807617B (ja)
AP (1) AP2006003562A0 (ja)
AR (1) AR045563A1 (ja)
AU (1) AU2004275700B2 (ja)
BR (1) BRPI0414269B8 (ja)
CA (2) CA2537876C (ja)
CR (1) CR8317A (ja)
DK (1) DK1670825T3 (ja)
EA (1) EA011669B1 (ja)
EC (1) ECSP066497A (ja)
ES (2) ES2618526T3 (ja)
GB (1) GB2405873A (ja)
GE (1) GEP20104922B (ja)
GT (1) GT200400181A (ja)
HK (2) HK1093212A1 (ja)
HN (1) HN2004000356A (ja)
HU (1) HUE033708T2 (ja)
IL (3) IL174016A (ja)
IS (1) IS3021B (ja)
MA (1) MA28092A1 (ja)
MX (2) MX346194B (ja)
MY (1) MY157376A (ja)
NL (1) NL1027009C2 (ja)
NO (1) NO343557B1 (ja)
NZ (3) NZ546369A (ja)
PA (1) PA8611701A1 (ja)
PE (1) PE20050376A1 (ja)
PL (1) PL1670825T3 (ja)
PT (1) PT1670825T (ja)
RS (1) RS20060171A (ja)
SG (2) SG176457A1 (ja)
SI (1) SI1670825T1 (ja)
TN (1) TNSN06080A1 (ja)
TW (2) TWI356063B (ja)
UA (1) UA90457C2 (ja)
UY (1) UY28507A1 (ja)
WO (1) WO2005030124A2 (ja)
ZA (1) ZA200601969B (ja)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110091451A1 (en) * 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
EP2377555A3 (en) * 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
AU2006220828A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-MAdCAM antibody compositions
JP2006249082A (ja) * 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 低減レベルの内毒素を有する抗m−csf抗体組成物
EP1913028B1 (en) * 2005-07-28 2015-03-04 Novartis AG Use of antibody to m-csf
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー M−csf特異的モノクローナル抗体およびその使用
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトgm−csfに結合するヒトのモノクローナル抗体並びにその抗原結合部分
TWI390034B (zh) * 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
AU2008214476A1 (en) * 2007-02-06 2008-08-14 Ribovax Biotechnologies S.A. Antibodies specific for varicella zoster virus
RS56743B1 (sr) * 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
US8268970B2 (en) * 2007-10-01 2012-09-18 Bristol-Myers Squibb Company Human antibodies that bind mesothelin, and uses thereof
JP2011502266A (ja) * 2007-10-31 2011-01-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Fms治療に対する応答を評価するバイオマーカー
RU2517596C2 (ru) * 2007-11-13 2014-05-27 Эвек Инк. МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ
ES2623653T3 (es) * 2008-01-04 2017-07-11 Baxalta Incorporated Anticuerpos anti-MIF
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI0909044B8 (pt) * 2008-03-14 2021-05-25 Transgene Sa anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010104747A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
PT2406286T (pt) 2009-03-10 2016-08-19 Baylor Res Inst Anticorpos anti-cd40 e seus usos
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2010132532A1 (en) * 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
EP3219723B1 (en) * 2009-08-27 2021-10-06 Novo Nordisk A/S Targeting tissue factor to activated platelets
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20120208208A1 (en) * 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
TWI651331B (zh) * 2010-05-04 2019-02-21 戊瑞治療有限公司 與集落刺激因子1受體(csf1r)結合之抗體類
HUE031778T2 (en) * 2010-05-14 2017-07-28 Univ Leland Stanford Junior Humanized and chimeric monoclonal antibodies against CD47
AU2011274363A1 (en) 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
AU2015234335B2 (en) * 2010-09-29 2017-09-28 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
SI3409287T1 (sl) 2010-09-29 2021-08-31 Agensys, Inc. Konjugati protitelo-zdravilo (ADC), ki se vežejo na proteine 191P4D12
CN102603649B (zh) * 2011-01-20 2016-05-25 赣南师范学院 一种以地巴唑为先导分子的荧光探针化合物及其制备方法
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
IN2014CN04183A (ja) 2011-11-08 2015-07-17 Pfizer
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014167088A1 (en) * 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
MX2016007533A (es) * 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
JP6964410B2 (ja) 2014-06-23 2021-11-10 ファイヴ プライム セラピューティクス インク コロニー刺激因子1受容体(csf1r)に結合する抗体で疾患を治療する方法
TW201632202A (zh) 2015-01-30 2016-09-16 諾華公司 乳癌之治療
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
MX2017016324A (es) 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
CN109071646A (zh) 2016-03-11 2018-12-21 供石公司 TGFβ1-结合免疫球蛋白及其用途
EP3522923A1 (en) 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
AU2018205231A1 (en) * 2017-01-06 2019-07-18 Scholar Rock, Inc. Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
EP4116327A1 (en) 2017-10-11 2023-01-11 Board Of Regents, The University Of Texas System Human pd-l1 antibodies and methods of use therefor
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
EP3768298A4 (en) 2018-03-23 2021-12-08 Board of Regents, The University of Texas System HUMAN ANTI-PD-L2 ANTIBODIES AND PROCESSES FOR USE
EP3768726A4 (en) * 2018-03-23 2021-12-22 Board of Regents, The University of Texas System DOUBLE SPECIFICITY ANTIBODIES FOR PD-L1 AND PD-L2 AND METHOD OF USING THEREOF
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
AU2019274655B2 (en) 2018-05-23 2023-03-09 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
JP7384835B2 (ja) 2018-05-23 2023-11-21 ファイザー・インク Cd3に特異的な抗体及びその使用
AU2019302642A1 (en) 2018-07-10 2021-02-25 Regeneron Pharmaceuticals, Inc. Modifying binding molecules to minimize pre-existing interactions
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
KR20220114049A (ko) 2019-12-17 2022-08-17 화이자 인코포레이티드 Cd47, pd-l1에 특이적인 항체, 및 그의 용도
WO2021124096A1 (en) 2019-12-18 2021-06-24 Pfizer Inc. Once daily cancer treatment regimen with a prmt5 inhibitor
JP7481856B2 (ja) 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
EP4118105A2 (en) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc fusion protein and uses thereof
IL298159A (en) 2020-05-13 2023-01-01 Pfizer Treatment methods and uses for cancer treatment
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3189590A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
AU2021339096A1 (en) 2020-09-14 2023-04-06 Pfizer Inc. Methods, therapies and uses for treating cancer
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
WO2022183112A2 (en) * 2021-02-26 2022-09-01 New York University Compositions and methods comprising antibodies that bind to covalent peptide conjugates
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023218320A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2023242769A1 (en) 2022-06-17 2023-12-21 Pfizer Inc. Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
WO2024009191A1 (en) 2022-07-05 2024-01-11 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5531159A (en) 1978-08-26 1980-03-05 Sumitomo Metal Ind Ltd Manufacture of high strength cold rolled steel plate for press working
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4504586A (en) * 1983-02-03 1985-03-12 Amgen Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
AU594045B2 (en) * 1985-02-05 1990-03-01 Chiron Corporation Recombinant colony stimulating factor-1
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
US5792450A (en) * 1985-02-05 1998-08-11 Chiron Corporation Purified human CSF-1
US6146851A (en) 1985-02-05 2000-11-14 Chiron Corporation DNA encoding NV2 (long form) and carboxy truncated fragments thereof
US5837229A (en) 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4868119A (en) * 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
MX9203130A (es) * 1986-05-06 1992-07-01 Genetics Inst Produccion de m-csf
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1339757C (en) * 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4929455A (en) * 1988-07-07 1990-05-29 Mallinckrodt, Inc. Flour-based pot pie crusts with improved texture
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DK0457804T3 (da) * 1989-02-10 1996-09-23 Chiron Corp M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
CA2062975A1 (en) 1989-07-14 1991-01-15 Gail F. Seelig Antagonists of gm-csf derived from the carboxyl terminus
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP0506855A1 (en) * 1989-12-15 1992-10-07 Chiron Corporation Cytokine antibody for the treatment of sepsis
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) * 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) * 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
CA2060741A1 (en) 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
JPH0595794A (ja) * 1991-10-04 1993-04-20 Otsuka Pharmaceut Co Ltd ヒトm−csf抗体及びヒトm−csfの測定法
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH08503121A (ja) 1991-12-10 1996-04-09 デイナ・フアーバー・キヤンサー・インステイテユート 中和反応性ヒト抗−gp120組換え抗体、それをコードするdnaおよびその使用
JPH067189A (ja) 1991-12-17 1994-01-18 Morinaga Milk Ind Co Ltd ヒトM−CSF β型ダイマ−に特異性を有するモノクロ− ナル抗体と、この抗体を産生するハイブリドーマ、お よびこの抗体の利用
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
DE69329247T2 (de) * 1992-06-09 2001-05-31 Chiron Corp Kristallisierung von m-csf
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
JPH06194367A (ja) 1992-12-25 1994-07-15 Morinaga Milk Ind Co Ltd リウマチ疾患の診断方法
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
PT804070E (pt) * 1993-03-09 2000-11-30 Genzyme Corp Isolamento de componentes de interesse a partir do leite.
JPH06319584A (ja) 1993-05-07 1994-11-22 Morinaga Milk Ind Co Ltd 抗m−csfモノクロ−ナル抗体と、この抗体を産生 するハイブリド−マ
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US5643763A (en) * 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
JPH11503914A (ja) 1995-04-21 1999-04-06 セル ジェネシス,インコーポレイテッド 大ゲノムdna欠失の生成
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
BR9710362A (pt) 1996-07-13 1999-08-17 Glaxo Group Ltd Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
BR9710381A (pt) 1996-07-18 1999-08-17 Pfizer Inibidores de metaloproteases de matriz - base de fosfinato
JP2000501423A (ja) 1996-08-23 2000-02-08 ファイザー インク. アリールスルホニルアミノヒドロキサム酸誘導体
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) * 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
PL335027A1 (en) 1997-02-03 2000-03-27 Pfizer Prod Inc Derivatives of arylsulphonylamino hydroxamic acid
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
EP0968290B1 (en) 1997-03-12 2004-12-15 SmithKline Beecham Corporation Anti-alphavbeta3 humanized monoclonal antibodies
EP2336168A1 (en) * 1997-04-15 2011-06-22 Sankyo Company Limited Novel protein and method for producing the protein
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
AU734009B2 (en) 1997-05-30 2001-05-31 Merck & Co., Inc. Novel angiogenesis inhibitors
SK1362000A3 (en) 1997-08-08 2000-10-09 Pfizer Prod Inc Aryloxyarylsulfonylamino hydroxamic acid derivatives
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
WO1999016755A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
CA2322749A1 (en) 1998-03-03 1999-09-10 Abgenix, Inc. Cd147 binding molecules as therapeutics
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU759226B2 (en) 1998-05-29 2003-04-10 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AUPP525198A0 (en) * 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DE69915004T2 (de) 1998-11-05 2004-09-09 Pfizer Products Inc., Groton 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
WO2000035956A1 (fr) * 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
IL143797A0 (en) * 1998-12-23 2002-04-21 Pfizer Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US6471429B1 (en) * 1999-01-29 2002-10-29 Canon Kabushiki Kaisha Sheet processing apparatus for discharging sheets in a bundle
AU5761900A (en) 1999-06-30 2001-01-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Human monoclonal antibodies to hiv-1 envelope glycoprotein gp120
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US6794132B2 (en) * 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US7135287B1 (en) 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
WO2001034177A2 (en) 1999-11-08 2001-05-17 The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health Method of treating a viral infection using antagonists of macrophage colony stimulating factor
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
EP1285084A1 (en) 2000-01-25 2003-02-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2001272925A1 (en) * 2000-05-26 2001-12-11 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2002059340A1 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Immunopolypeptides to hepatitis c virus
US7192582B2 (en) 2001-02-12 2007-03-20 Medarex, Inc. Human monoclonal antibodies to FC alpha receptor (CD89)
US20020146753A1 (en) * 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
PT1391464E (pt) * 2001-04-27 2007-11-15 Kirin Pharma Kk Anticorpo monoclonal anti-cd40
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗cd40モノクローナル抗体
FI112501B (fi) 2001-05-18 2003-12-15 Valtion Teknillinen Heveiiniä sitovat monoklonaaliset vasta-aineet
CA2447602C (en) 2001-05-18 2011-11-01 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
JP2005168497A (ja) 2001-05-18 2005-06-30 Kirin Brewery Co Ltd 抗trail−r抗体およびその用途
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
PT1410011E (pt) 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
US20040259153A1 (en) 2001-08-22 2004-12-23 Yoshikazu Kurosawa Methods for selecting biding molecule
JP3729841B2 (ja) 2001-10-15 2005-12-21 麒麟麦酒株式会社 抗hla−dr抗体の利用
JP3665324B2 (ja) 2001-10-15 2005-06-29 麒麟麦酒株式会社 抗hla−dr抗体
AU2002364954A1 (en) 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP1461082A4 (en) 2001-12-03 2006-06-28 Abgenix Inc ANTIBODIES AGAINST THE TUMOR ANTIGEN OF CARBON IX ANHYDRASE (CA IX)
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
EP1322146A1 (en) 2001-12-18 2003-06-25 Phoenix Precision Technology Corporation Method of electroplating solder bumps on an organic circuit board
NZ534174A (en) 2002-01-09 2007-03-30 Medarex Inc An isolated human monoclonal antibody which binds to human CD30
CA2476625A1 (en) 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
CA2478386A1 (en) 2002-03-21 2003-10-02 Eli Lilly And Company Antagonistic anti-hfas ligand human antibodies and fragments thereof
CA2483337C (en) 2002-04-23 2015-10-27 The Scripps Research Institute Expression of polypeptides in chloroplasts, and compositions and methods for expressing same
CA2484155C (en) 2002-04-29 2015-10-13 Baxter International Inc. Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
ATE466885T1 (de) * 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
CL2003002461A1 (es) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
WO2004050032A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies against drugs of abuse
MXPA05005925A (es) * 2002-12-02 2006-02-08 Abgenix Inc Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
US20050009136A1 (en) * 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
CA2519528C (en) 2003-03-19 2016-01-26 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
EP1625162A2 (en) 2003-05-06 2006-02-15 Albert Einstein College Of Medicine Of Yeshiva University Compositions and methods for treatment of cryptococcosis
CA2525120C (en) 2003-05-14 2013-04-30 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
JP4999158B2 (ja) 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌(bachillusanthracis)の感染防御抗原に対するヒトモノクローナル抗体
WO2004108078A2 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals Inc. Rationally designed antibodies
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
UY28424A1 (es) * 2003-07-22 2005-02-28 Schering Ag Anticuerpos rgi y usos de los mismos.
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
JP2007528720A (ja) 2003-08-12 2007-10-18 ダイアックス コーポレイション Tie1結合リガンド
WO2005019270A2 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005034733A2 (en) 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
CN1886426A (zh) 2003-11-07 2006-12-27 伊姆尼斯公司 结合白细胞介素-4受体的抗体
CA2543631A1 (en) 2003-11-07 2005-05-26 Amgen Inc. Monkey immunoglobulin sequences
JP4870348B2 (ja) 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
HUE035520T2 (en) 2003-12-10 2018-05-28 Squibb & Sons Llc Interferon alpha antibodies and their use
US20050191293A1 (en) 2003-12-10 2005-09-01 Shrikant Deshpande IP-10 antibodies and their uses
JP4712724B2 (ja) 2003-12-23 2011-06-29 クルセル ホランド ベー ヴェー CD1aに対するヒト結合分子
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
CA2553946C (en) 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
US7271245B2 (en) 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
WO2005086713A2 (en) 2004-03-04 2005-09-22 Kirin Brewery Co., Ltd. Role of human endothelial precursor cells and vascular pericytes tumor in angiogenesis
US20050260679A1 (en) 2004-03-19 2005-11-24 Sirid-Aimee Kellerman Reducing the risk of human anti-human antibodies through V gene manipulation
RU2368622C2 (ru) * 2004-04-13 2009-09-27 Ф.Хоффманн-Ля Рош Аг Антитела к р-селектину
WO2005109266A1 (en) 2004-05-07 2005-11-17 Snap-On Incorporated Tool monitoring system
WO2006014498A2 (en) 2004-07-06 2006-02-09 Bioren, Inc. Universal antibody libraries
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2006007850A1 (en) 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション hK1結合タンパク質
WO2006017759A2 (en) 2004-08-05 2006-02-16 Kirin Brewery Co., Ltd. Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2005272848A1 (en) 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
EP1791867A2 (en) 2004-08-23 2007-06-06 Genesto A/S Binding member towards pneumolysin
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
JP2008514730A (ja) 2004-10-01 2008-05-08 メダレックス, インク. Cd30陽性リンパ腫の処置の方法
KR100619546B1 (ko) 2004-10-05 2006-09-04 아주대학교산학협력단 히스톤 h2a 및/또는 h2b에 대한 인간 모노클로날자가항체 및 그 단편
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
JP2008521411A (ja) 2004-11-30 2008-06-26 キュラジェン コーポレイション Gpnmbに対する抗体およびその使用
CA2595610C (en) * 2004-12-21 2013-03-05 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
AU2006208286A1 (en) 2005-01-26 2006-08-03 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CA2598561C (en) 2005-02-18 2014-01-21 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl residues
JP2006249082A (ja) 2005-03-08 2006-09-21 Pharmacia & Upjohn Co Llc 低減レベルの内毒素を有する抗m−csf抗体組成物
AU2006220828A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-MAdCAM antibody compositions
US7988971B2 (en) 2005-03-14 2011-08-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies against Hendra and Nipah viruses
AU2006230413B8 (en) 2005-03-31 2011-01-20 Xencor, Inc Fc variants with optimized properties
EP1874820A4 (en) 2005-04-20 2010-09-22 Amgen Fremont Inc HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
EP1913028B1 (en) 2005-07-28 2015-03-04 Novartis AG Use of antibody to m-csf
JP5457671B2 (ja) 2005-07-28 2014-04-02 ノバルティス アーゲー M−csf特異的モノクローナル抗体およびその使用
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2621371C (en) * 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
PT2655357T (pt) 2010-12-20 2016-09-28 Merck Serono Sa Derivados indazolil-triazol como inibidores de irak
KR101460477B1 (ko) 2013-06-18 2014-11-10 주식회사 엘지화학 연신 적층체, 박형 편광자의 제조 방법, 이를 이용하여 제조되는 박형 편광자 및 이를 포함하는 편광판
JP6319584B2 (ja) 2015-02-27 2018-05-09 京セラドキュメントソリューションズ株式会社 画像形成システム

Similar Documents

Publication Publication Date Title
JP2011083291A5 (ja)
JP2018504105A5 (ja)
JP2019533989A5 (ja) 抗pd−1抗体及びその使用
JP2017114866A5 (ja)
JP2020531048A5 (ja)
JP2016511750A5 (ja)
IL256871B2 (en) Constructs for bispecific antibodies binding to dll3 and cd3 and uses thereof
JP2019527047A5 (ja)
HRP20171741T1 (hr) Proteini koji se vežu na ljudski antigen c-fms
JP2020510422A5 (ja)
JP2018524001A5 (ja)
JP2012116856A5 (ja)
JP2014534242A5 (ja)
JP2011505146A5 (ja)
JP2016514463A5 (ja)
JP2019523221A5 (ja)
JP2019501883A5 (ja)
FI3283524T3 (fi) Bispesifisiä vasta-ainekonstrukteja cdh3:lle ja cd3:lle
JP2010511388A5 (ja)
RU2017128882A (ru) Антитела к биотину и способы их применения
JP2017523786A5 (ja)
JP2013523166A5 (ja)
RU2016114074A (ru) Анти-rspo антитела и способы применения
JP2013056885A5 (ja)
JP2014526898A5 (ja)